PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27599525-12	2017	These indicated that selumetinib effectively prevented skeletal muscle wasting in cancer cachexia model through ERK inhibition and AKT activation in gastrocnemius muscle via cross-inhibition.	AZD 6244	21-32	thymoma viral proto-oncogene 1	Mus musculus	131-134	
27599525-0	2017	Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.	AZD 6244	0-11	thymoma viral proto-oncogene 1	Mus musculus	99-102	
27599525-11	2017	Detailed analysis of the mechanism revealed AKT and mTOR were activated, while ERK, FoxO3a, and GSK3beta were inhibited in the selumetinib -treated cachexia group.	AZD 6244	127-138	thymoma viral proto-oncogene 1	Mus musculus	44-47	
25326806-8	2015	Western blot analysis and immunohistochemical staining revealed that treatment with AZD6244 or BEZ235 could significantly reduce the phosphorylation level of ERK1/2 or AKT in HCT116 tumor tissues.	AZD 6244	84-91	thymoma viral proto-oncogene 1	Mus musculus	168-171	
34735879-7	2021	As a result, AZD-6244 enhanced the conversion of iPS cells into CSCs and upregulated AKT phosphorylation as same as GDC-0879 and PD0325901.	AZD 6244	13-21	thymoma viral proto-oncogene 1	Mus musculus	85-88